Journal Home
Search for

Volume 20, Issue 8, Pages 545-552 (August 2010)


View previous. 4 of 12 View next.

Effect of hypertriglyceridemia on the pharmacokinetics and blood–brain barrier penetration of clozapine and norclozapine following administration to rats

Pavel GershkovichaCorresponding Author Informationemail address, Olena Sivaka, Aishwariya Sharmaa, Alasdair M. Barrb, Ric Procyshync, Kishor M. Wasana

Received 17 October 2009; received in revised form 31 December 2009; accepted 21 January 2010. published online 17 February 2010.

Abstract 

There is a long-term discussion in the literature concerning the possible link between the improved efficacy of clozapine treatment and elevated plasma triglyceride levels, but no mechanistic studies have been performed to date. The aim of this work was to investigate whether the postprandial hypertriglyceridemia affects the pharmacokinetics and brain distribution of clozapine and norclozapine. Experimental hypertriglyceridemia in rats was induced by oral administration of peanut oil and the pharmacokinetic parameters and brain penetration of clozapine and norclozapine following administration of clozapine were compared to normotriglyceridemic control animals. Moderately increased clearance of clozapine was found in hypertriglyceridemic animals compared to control group. No changes were found in penetration of compounds across the blood–brain barrier (BBB). Taken together, the results do not support the hypothesis that hypertriglyceridemia improves the effect of clozapine by altered pharmacokinetics of clozapine and norclozapine and their increased penetration across the BBB.

a Division of Pharmaceutics and Biopharmaceutics, Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, BC, Canada

b Department of Anesthesiology, Pharmacology and Therapeutics, University of British Columbia, Vancouver, BC, Canada

c BC Mental Health and Addictions Research Institute, Vancouver, BC, Canada

Corresponding Author InformationCorresponding author. Division of Pharmaceutics and Biopharmaceutics, Faculty of Pharmaceutical Sciences, University of British Columbia, 2146 East Mall Avenue, Vancouver, BC, Canada V6T 1Z3. Tel.: +1 604 822 6772; fax: +1 604 822 3035.

PII: S0924-977X(10)00018-0

doi:10.1016/j.euroneuro.2010.01.002


View previous. 4 of 12 View next.